MarioSznolMD

Oncology • New Haven, CT

Hematologic Oncology, Melanoma

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Join to view full profile

Dr. Sznol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sznol's full profile

Already have an account?

Office
333 Cedar Street, WWW222
New Haven, CT
New Haven, CT 06520
Phone+1 203-200-6622

Fax+1 203-785-3788
Is this information wrong?

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1985 - 1987
Baylor College of MedicineResidency, Internal Medicine, 1982 - 1985
Baylor College of MedicineClass of 1982

Certifications & Licensure

CT State Medical License 2000 - 2024
MD State Medical License 1987 - 2001
TX State Medical License 1983 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2013
Join now to see all

Clinical Trials

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Start of enrollment: 1996 Oct 01
Terminated
Phase 1
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors Start of enrollment: 1998 May 01
Completed
Phase 1
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy Start of enrollment: 1999 Aug 01
Completed
Phase 1
3-AP in Treating Patients With Advanced Cancer Start of enrollment: 2000 May 01
Completed
Phase 1
VNP20009 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 May 01
Completed
Phase 1
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 1
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2001 Mar 01
Completed
Phase 1
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome Start of enrollment: 2002 Apr 01
Completed
Phase 1
VNP40101M in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 1
3-AP in Treating Patients With Advanced Prostate Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 2
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
3-AP and Cytarabine in Treating Patients With Hematologic Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 1
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies Start of enrollment: 2003 Jun 01
Completed
Phase 1
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2005 Jul 01
Completed
Phase 1
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy Start of enrollment: 2006 Feb 01
Terminated
Phase 1
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) Start of enrollment: 2009 Jul 01
Completed
Phase 1
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Start of enrollment: 2010 Sep 28
Completed
Phase 1
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection Start of enrollment: 2022 Nov 08
Terminated
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

How Far We've Come.
Jeffrey S Weber, Mario Sznol> ;Cancer Journal. 2024 Mar 25
2 citations
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progres...
Weiss, S., Sznol, M., Shaheen, M., Berciano-Guerrero, M., Couselo, E., Rodríguez-Abreu, D., Boni, V., Schuchter, L., Gonzalez-Cao, M., Arance, A., Wei, W., Ganti, A., ...> ;Clinical Cancer Research. 2024 Jan 5
1 citations
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
Daniel M Kerekes, Alexander E Frey, Elizabeth H Prsic, Thuy T Tran, James E Clune, Mario Sznol, Harriet M Kluger, Howard P Forman, Robert D Becher, Kelly L Olino, Saji...> ;JAMA Oncology. 2024 Mar 1
Immunotherapy utilization in stage IIIA melanoma: less may be more.
Frey, A., Clune, J., Kerekes, D., Khan, S., Tran, T., Kluger, H., Ariyan, S., Sznol, M., Ishizuka, J., Olino, K.> ;Frontiers in Oncology. 2024 Jan 1
2 citations
Interferon-stimulated neutrophils as a predictor of immunotherapy response.
Benguigui, M., Cooper, T., Kalkar, P., Schif-Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Menachem, R., Haj-Shomaly, J., Vorontsova, A., Ra...> ;Cancer Cell. 2024 Feb 12
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Adriana M Kahn, Curtis J Perry, Katrina Etts, Harriet Kluger, Mario Sznol> ;The Oncologist. 2024 Apr 4
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L Perdigoto, Wei Wei, Gail Anderson, William Damsky, Mic...> ;Molecular Cancer. 2023 Nov 14
8 citations
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V Long, Paolo A Ascierto, James Larkin, Mario Sznol, Fabio Franke, Tudor E Ciuleanu, Caio Pereira, Eva Muñoz Couselo, ...> ;Journal of Clinical Oncology. 2023 Oct 20
3 citations
CD4 T cells and toxicity from immune checkpoint blockade.
Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y Chen, Mario Sznol, Ruth Halaban, Aadel A Chaudhuri, Aaron M Newman> ;Immunological Reviews. 2023 Sep 1
Determinants of overall survival in patients with metastatic uveal melanoma.
Patrick Demkowicz, Renelle Pointdujour-Lim, Sofia Miguez, Yesung Lee, Bailey S C L Jones, Christopher A Barker, Marcus Bosenberg, David H Abramson, Alexander N Shousht...> ;Cancer. 2023 Oct 15
Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety...
Annika Belzer, Jolanta Pach, Ryland D Mortlock, James Clune, Kelly Olino, Mario Sznol, Aarti Bhatia, Barbara Burtness, Sean Christensen, Jonathan S Leventhal> ;JAAD International. 2023 Jun 1
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Brooke Horowitch, Daniel Y Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet Kluger,...> ;Clinical Cancer Research. 2023 Aug 1
3 citations
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial c...
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee...> ;Journal for Immunotherapy of Cancer. 2023 May 1
1 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, Joh...> ;Journal of Clinical Oncology. 2023 Feb 10
2 citations
Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
Sofia Miguez, Ryan Y Lee, Alison X Chan, Patrick C Demkowicz, Bailey S C L Jones, Christopher P Long, David H Abramson, Marcus Bosenberg, Mario Sznol, Harriet Kluger, ...> ;Ophthalmology. 2023 Jun 1
3 citations
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Matthew Austin, Bryden Considine, Shlomit Jessel, David Schoenfeld, Man Yee Merl, Michael Hurwitz, Mario Sznol, Harriet Kluger, Dizman, N.> ;Clinical Genitourinary Cancer. 2023 Apr 1
7 citations
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications.
Mario Sznol, Naiyer Rizvi> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
11 citations
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim, T., Burris, H., de Miguel Luken, M., Pishvaian, M., Bang, Y., Gordon, M., Awada, A., Camidge, D., Hodi, F., McArthur, G., Miller, W., Cervantes, A., Chow, L., Les...> ;Clinical Cancer Research. 2022 Aug 15
20 citations
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
5 citations
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma.
Victor O Oria, Hongyi Zhang, Christopher R Zito, Chetan K Rane, Xian-Yong Ma, Olivia K Provance, Thuy T Tran, Adebowale Adeniran, Yuval Kluger, Mario Sznol, Marcus W B...> ;Cellular and Molecular Life Sciences. 2022 Jun 23
5 citations
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal...> ;European Urology. 2022 Oct 1
1 citations
Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune...> ;Nature Communications. 2022 May 10
9 citations
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhur...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
16 citations
Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune...> ;Nature Communications. 2022 Feb 23
109 citations
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Alexander X Lozano, Aadel A Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D Vesely, Abul Usmani, Brandon E Turner, Chloé B Steen, Bogdan A L...> ;Nature Medicine. 2022 Feb 1
Join now to see all

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

Case Presentations. Managing Immune-Related Adverse Events: The Challenge to Maximize the Risk/Benefit Ratio (A Case-Based Discussion)
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Chair - Hematologic Malignancies and CAR-T Cell Therapy. Hematologic Malignancies and CAR-T Cell Therapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Chair - Basic Principles of Immunotherapy. Basic Principles of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Immunotherapy Basics. Basic Principles of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Join now to see all

Press Mentions

Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 4th, 2022
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to Its Scientific Advisory BoardMarch 24th, 2022
NextCure Announces Three New Members of Its Scientific Advisory BoardOctober 19th, 2021
Join now to see all